<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074551</url>
  </required_header>
  <id_info>
    <org_study_id>HM-AMOS-301</org_study_id>
    <nct_id>NCT04074551</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia</brief_title>
  <official_title>A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and&#xD;
      Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with&#xD;
      Hypertension and Dyslipidemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in LDL-C (%)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Experimental, Active Control 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Experimental, Active Control 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL-C (%)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Experimental, Active Control 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Experimental, Active Control 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL-C (%)</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TC, HDL-C, TG (%)</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting distolic blood pressure</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject achieving LDL-C control</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving blood pressure control</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responder for blood pressure</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject achieving both LDL-C and blood pressure control</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1701</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HGP0904, HGP0608</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HGP0608, HCP1306</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1701</intervention_name>
    <description>HCP1701</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin and Ezetimibe</intervention_name>
    <description>Rosuvastatin and Ezetimibe</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 19&#xD;
&#xD;
          -  Patients who understood the contents and purpose of this trial and signed informed&#xD;
             consent form&#xD;
&#xD;
          -  Patients with essential hypertension and dyslipidemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg&#xD;
             for mean sitDBP&#xD;
&#xD;
          -  Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg&#xD;
&#xD;
          -  Concomitant administration of cyclosporine&#xD;
&#xD;
          -  Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase&#xD;
             inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy&#xD;
&#xD;
          -  Hereditary angioedema or medical history of angioedema in the treatment of ACE&#xD;
             inhibitors or angiotensin II receptor blockers&#xD;
&#xD;
          -  Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse&#xD;
             effect to statin&#xD;
&#xD;
          -  CPK normal range &gt; 2 times&#xD;
&#xD;
          -  Secondary hypertension and suspected secondary hypertension&#xD;
&#xD;
          -  Orthostatic hypotension with symptoms&#xD;
&#xD;
          -  Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)&#xD;
&#xD;
          -  Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)&#xD;
&#xD;
          -  Active gout or hyperuricemia(uric acid ≥ 9mg/dL)&#xD;
&#xD;
          -  IDDM or uncontrolled type 2 diabetes mellitus (HbA1c &gt; 9%)&#xD;
&#xD;
          -  Ventricular arrhythmia&#xD;
&#xD;
          -  Medical history&#xD;
&#xD;
               -  Severe heart disease(heart failure of NYHA class III-IV)&#xD;
&#xD;
               -  Severe cerebrovascular disease within 6 months (cerebral infarction, cerebral&#xD;
                  hemorrhage), hypertensive encephalopathy, transient cerebral ischemic attack(TIA)&#xD;
&#xD;
               -  Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery&#xD;
                  disease, aortic stenosis, hemodynamically significant stenosis in aortic valve or&#xD;
                  mitral valve&#xD;
&#xD;
               -  Ischemic heart disease(myocardial infarction, angina) within 6months&#xD;
&#xD;
               -  Angioplasty or coronary artery bypass graft(CABG) surgery within 6months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-si</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

